{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T08:52:56Z","timestamp":1719996776275},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81000732","81471946"],"award-info":[{"award-number":["81000732","81471946"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science & Technology Commission of China","award":["2013ZX10002002"],"award-info":[{"award-number":["2013ZX10002002"]}]},{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["cstc2015jcyjA10023","cstc2013jcyjC10002"],"award-info":[{"award-number":["cstc2015jcyjA10023","cstc2013jcyjC10002"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Education Commission","award":["CYB15099"],"award-info":[{"award-number":["CYB15099"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.antiviral.2015.12.009","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T02:31:05Z","timestamp":1451356265000},"page":"99-107","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation"],"prefix":"10.1016","volume":"126","author":[{"given":"Ying-ying","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-fei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan-xin","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-long","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie-li","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.12.009_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2015.12.009_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.510270628","article-title":"Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group","volume":"27","author":"Allen","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0016-5085(03)00939-9","article-title":"Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase","volume":"125","author":"Angus","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib4","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2007.12.024","article-title":"Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response","volume":"48","author":"Baldick","year":"2008","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2015.12.009_bib5","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.22211","article-title":"Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance","volume":"47","author":"Baldick","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/nar\/20.2.195","article-title":"Expression of the P-protein of the human hepatitis B virus in a vaccinia virus system and detection of the nucleocapsid-associated P-gene product by radiolabelling at newly introduced phosphorylation sites","volume":"20","author":"Bartenschlager","year":"1992","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2015.12.009_bib7","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1099\/vir.0.80297-0","article-title":"Detection and characterization of cytoplasmic hepatitis B virus reverse transcriptase","volume":"85","author":"Cao","year":"2004","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2015.12.009_bib8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/hep.510270634","article-title":"Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy","volume":"27","author":"Chayama","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib9","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1128\/AAC.45.9.2495-2501.2001","article-title":"In\u00a0vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil","volume":"45","author":"Chin","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.009_bib10","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1128\/AAC.43.8.2017","article-title":"Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA","volume":"43","author":"Delaney","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.009_bib11","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1128\/AAC.45.6.1705-1713.2001","article-title":"Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus","volume":"45","author":"Delaney","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.009_bib12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/hep.20388","article-title":"A\u00a0new strategy for studying in\u00a0vitro the drug susceptibility of clinical isolates of human hepatitis B virus","volume":"40","author":"Durantel","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib13","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.44.12.3402-3407.2000","article-title":"Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus","volume":"44","author":"Fu","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.009_bib14","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/jac\/dkr388","article-title":"Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B","volume":"66","author":"Fung","year":"2011","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2015.12.009_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000360950","article-title":"Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants","volume":"57","author":"Glebe","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib16","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1128\/JVI.69.9.5437-5444.1995","article-title":"A\u00a0novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients","volume":"69","author":"Gunther","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.12.009_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.antiviral.2008.09.004","article-title":"Dynamics of hepatitis B virus resistance to entecavir in a nucleoside\/nucleotide-naive patient","volume":"81","author":"Guo","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2015.12.009_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jviromet.2009.05.017","article-title":"A\u00a0new strategy for constructing in\u00a0vitro replication-competent 1.3 copies of hepatitis B virus genome","volume":"161","author":"Hu","year":"2009","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.antiviral.2015.12.009_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jmv.22260","article-title":"Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy","volume":"84","author":"Hu","year":"2012","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.antiviral.2015.12.009_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/135965350400900311","article-title":"In\u00a0vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir","volume":"9","author":"Lada","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2015.12.009_bib21","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1128\/AAC.42.8.2128","article-title":"The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA","volume":"42","author":"Ladner","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.009_bib22","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1128\/AAC.46.8.2525-2532.2002","article-title":"Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in\u00a0vitro","volume":"46","author":"Levine","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.009_bib23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2015.12.009_bib24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management","volume":"46","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib26","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/hep.510270243","article-title":"Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective","volume":"27","author":"Melegari","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib27","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1128\/JVI.66.7.4107-4116.1992","article-title":"The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly","volume":"66","author":"Nassal","year":"1992","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.12.009_bib28","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1172\/JCI5882","article-title":"Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors","volume":"103","author":"Ono-Nita","year":"1999","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.antiviral.2015.12.009_bib29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/hep.510290340","article-title":"YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in\u00a0vitro full-length viral DNA transfection","volume":"29","author":"Ono-Nita","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib30","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1128\/JVI.02507-07","article-title":"Differential inhibition of nuclear hormone receptor-dependent hepatitis B virus replication by the small heterodimer partner","volume":"82","author":"Oropeza","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.12.009_bib31","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.510290119","article-title":"Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance","volume":"29","author":"Pichoud","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","article-title":"In\u00a0vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents","volume":"12","author":"Qi","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2015.12.009_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1128\/JVI.71.1.345-353.1997","article-title":"Posttranscriptional regulation of hepatitis B virus replication by the precore protein","volume":"71","author":"Scaglioni","year":"1997","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.12.009_bib34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/315368","article-title":"Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B","volume":"181","author":"Seigneres","year":"2000","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.12.009_bib35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/jhep.2002.35070","article-title":"Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses","volume":"36","author":"Seigneres","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/135965350501000612","article-title":"Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir","volume":"10","author":"Sheldon","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2015.12.009_bib37","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1128\/JVI.75.11.5108-5118.2001","article-title":"Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier","volume":"75","author":"Sprinzl","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.12.009_bib38","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.009_bib39","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1038\/emi.2013.10","article-title":"Hepatitis B virus genetic variants: biological properties and clinical implications","volume":"2","author":"Tong","year":"2013","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.antiviral.2015.12.009_bib40","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2003.09.022","article-title":"Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient","volume":"39","author":"Villeneuve","year":"2003","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2015.12.009_bib41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2006.11.016","article-title":"Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient","volume":"46","author":"Villet","year":"2007","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2015.12.009_bib42","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/hep.510280629","article-title":"Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in\u00a0vitro","volume":"28","author":"Xiong","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.009_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2003.07.003","article-title":"In\u00a0vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector","volume":"61","author":"Yang","year":"2004","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2015.12.009_bib44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939759","article-title":"In\u00a0vitro models for studying hepatitis B virus drug resistance","volume":"26","author":"Zoulim","year":"2006","journal-title":"Semin. Liver Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T19:52:59Z","timestamp":1653940379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215300486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":44,"alternative-id":["S0166354215300486"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.12.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}